Stent News and Research

RSS

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

Boston Scientific Corporation today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow to the muscles (claudication).

10 Jan 2011

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

5 Jan 2011

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the GORE® C3 Delivery System to deploy the GORE® EXCLUDER® AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

5 Jan 2011

Boston Scientific acquires Sadra Medical

Boston Scientific Corporation today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California. The transaction follows the definitive merger agreement announced on November 19, 2010.

4 Jan 2011

Eighth Annual CTO Summit and Left Main Coronary Interventions Course to be held Feb. 14-16, in New York City

The Eighth Annual Chronic Total Occlusion Summit and Left Main Coronary Interventions Course is a three-day conference featuring state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions and left main coronary interventions.

4 Jan 2011

Promising initial data from STABLE clinical trial for endovascular treatment of Type B aortic dissection

Study investigators reported positive steps in Cook Medical's efforts to gain FDA approval of the treatment assessed in the STABLE clinical trial, designed to evaluate the safety and efficacy of a proximal endograft and a distal uncovered stent for the endovascular treatment of Type B aortic dissection for purposes of seeking FDA approval. The findings were presented by Dr. Joseph Lombardi at the 37th annual VEITHsymposium.

23 Dec 2010

St. Luke’s second in nation to perform EVAR with Endurant AAA Stent Graft System

An 80-year-old patient at St. Luke's Episcopal Hospital (St. Luke's) in Houston became the second in the nation to be treated with a newly approved FDA device for an abdominal aortic aneurysm (AAA). The condition, often called, "the silent killer," is a dangerous bulge or ballooning in the main artery of the body that typically causes no symptoms until it ruptures.

23 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

FDA approves Medtronic Endurant AAA Stent Graft System for abdominal aortic aneurysms

An estimated 1.2 million people in the United States have an abdominal aortic aneurysm (AAA) - a dangerous bulge or ballooning in their bodies' main artery that typically causes no symptoms until it ruptures, which can be deadly - and most of them don't know it. But for those with a known AAA of a certain size, there's a new medical device for a safe and effective treatment option that doesn't require major surgery, an extended hospital stay and a long recovery period.

21 Dec 2010

REVA raises A$85 million through IPO

REVA Medical, Inc. is pleased to announce that its Initial Public Offering (the Offer) has closed and that the Company has raised $A85,000,003.

21 Dec 2010

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the first patient has been enrolled in the pivotal trial to evaluate the Tryton Side Branch Stent System™ for the treatment of coronary artery disease.

20 Dec 2010

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Opsens Inc. today unveiled the EasyWire, developed by its medical division for the growth market of Fractional Flow Reserve for coronary lesion assessment.

20 Dec 2010

Spartan RX CYP2C19 DNA testing system receives European CE Mark certification

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced its Spartan RX CYP2C19 received a CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices. The CE Mark certification allows commercial distribution in Europe as well as in all countries recognizing the CE Mark in the Middle East, Africa, Latin America, and Asia-Pacific regions.

20 Dec 2010

InspireMD presents long-term data of MGuard stent technology at the ICI

InspireMD, developer of the novel MGuard(TM), a combination of a coronary stent merged with an embolic protection specifically designed for Acute MI (AMI) patients, received significant exposure at the ICI, Innovations in Interventional Cardiology, meeting this week in Tel-Aviv. InspireMD presented long-term data, including two years of clinical follow-up, to support the Company's MGuard stent technology.

17 Dec 2010

FFR-guided percutaneous coronary intervention provides cost-saving benefits

St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.

17 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

The Baltimore Sun: Stent sellers were allowed inside lab despite hospital ban

News outlets examine how the marketing of medical devices and treatments impacts health care costs and physicians' decisions.

16 Dec 2010

Demand for clinical research professionals double

ResourcingPoint announces that demand for clinical research professional placement has doubled in the last two months. An increase in clinical activity across the industry, coupled with a strategic expansion of the ResourcingPoint database of professional staff, has enabled significant clinical outsourcing growth for the company. A variety of different companies, from emerging device to large pharma and CROs, rely on ResourcingPoint for their contracting needs.

15 Dec 2010

Endologix acquires Nellix

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has completed the acquisition of Nellix, Inc. Nellix has developed a revolutionary new device for the treatment of Abdominal Aortic Aneurysms (AAAs) that is expected to address the limitations of existing endovascular aneurysm repair (EVAR) devices and expand the global AAA market. Endologix announced its agreement to acquire Nellix on October 27, 2010.

13 Dec 2010

Stent News and Research

Further Reading

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

Boston Scientific acquires Sadra Medical

Eighth Annual CTO Summit and Left Main Coronary Interventions Course to be held Feb. 14-16, in New York City

Promising initial data from STABLE clinical trial for endovascular treatment of Type B aortic dissection

St. Luke’s second in nation to perform EVAR with Endurant AAA Stent Graft System

Top ten advances in cardiovascular, stroke research in 2010

FDA approves Medtronic Endurant AAA Stent Graft System for abdominal aortic aneurysms

REVA raises A$85 million through IPO

Tryton initiates enrollment in Side Branch Stent System trial for coronary artery disease

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Spartan RX CYP2C19 DNA testing system receives European CE Mark certification

InspireMD presents long-term data of MGuard stent technology at the ICI

FFR-guided percutaneous coronary intervention provides cost-saving benefits

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

The Baltimore Sun: Stent sellers were allowed inside lab despite hospital ban

Demand for clinical research professionals double

Endologix acquires Nellix

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News